DXVX Accelerates Global Talent Recruitment to Boost R&D Efforts

DXVX is actively recruiting global talent one after another to accelerate the development of obesity treatments and other drugs.

On the 20th, DXVX announced that it recently invited Dr. Namjun Cho, a leading expert in infectious diseases and biomaterials medicine, as an advisor to the Americas Business Division, and recruited Seongnyeo Shim, a former global big pharma executive, as Vice President and Head of the Product Development Division.

Dr. Namjun Cho is a chaired professor in the Department of Materials Science and Engineering at Nanyang Technological University (NTU) in Singapore and also serves as the project leader for the Antiviral Drug Discovery Centers for Pathogens of Pandemic at Stanford University School of Medicine, funded by the U.S. National Institute of Allergy and Infectious Diseases (NIAID). He leads diverse research areas ranging from infectious disease medicine and antiviral peptide technology to the development of environmentally friendly plastic alternatives, having published over 290 papers in top-tier journals such as Nature. Professor Cho also serves as an advisor to the governments of Singapore, Korea, and Hungary.

Vice President Seongnyeo Shim is an expert with project leadership experience at global and domestic pharmaceutical and bio companies including Merck, GlaxoSmithKline (GSK), Teva, Samsung Biologics, and Celltrion.

Through the recruitment of such global pharmaceutical and bio talents, DXVX plans to establish countermeasures against newly emerging 'Disease X' such as vaccines, immunity, and infectious diseases, and to accelerate the development of its current pipeline.

A DXVX official stated, "For the oral obesity treatment, we plan to actively pursue partnering negotiations considering various options such as joint development and early licensing out, while conducting additional studies including animal testing alongside early filing of multiple substance patents. We will invite outstanding global talents to focus on accelerating the development and early commercialization of more advanced new drugs and therapies."